Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xianmei Zhou has a total of 202 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Xu

    School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China

    20 shared publications
  • Hailang He

    Affiliated Hospital of Nanjing University of Chinese Medicine, Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, China

    19 shared publications
  • Zhichao Wang

    Department of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    18 shared publications
  • Di Han

    Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital Of Chinese Medicine, Nanjing, China; Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China

    16 shared publications
  • Fanchao Feng

    Department of Pulmonary and Critical Care Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    15 shared publications
  • Yong Xu

    School of Chinese Medicine, Nanjing University of Chinese Medicine, China

    13 shared publications

Latest Publications

  • Open Access

    Integrative network toxicology and pharmacology reveal that kaempferol alleviates BaP-triggered pulmonary fibrosis via suppressing Ras/COX-2-dependent cellular senescence

    by Qi Zhao, Dongwei Zhu, Zhichao Wu, Xiaolin Xia, Yehui Li, Aojie Guo, Yong Xu, Xianmei Zhou

    Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease. Benzo[a]pyrene (BaP), a major constituent of cigarette smoke and air pollution, has been closely associated with pulmonary fibrosis. However, its molecular mechanism remains unclear. The natural flavonoid kaempferol possesses anti-inflammatory and antioxidant properties. However, its effects and mechanisms in BaP-induced pulmonary fibrosis remain unclear. Objectives: This study aimed to predict potential targets of BaP-induced fibrosis and kaempferol intervention in BaP-induced IPF, and to validate whether kaempferol reverses BaP-induced epithelial senescence and fibrosis via the Ras/COX-2 signaling pathway in vitro . Methods: Network toxicology, network pharmacology, machine learning, and molecular docking were integrated to predict potential targets of BaP-induced fibrosis and kaempferol intervention, followed by GO and KEGG pathway enrichment analyses. Additionally, virtual knockout analysis was performed to explore the regulatory relationships among Ras, COX-2, and cellular senescence. MLE-12 cells were used as an in vitro model, and senescence-related indicators were assessed by SA-β-gal staining, Western blot, and ELISA. Results: KEGG enrichment analysis revealed that these targets were significantly enriched in the Ras signaling pathway. Molecular docking confirmed that kaempferol exhibited good binding affinity for the above target proteins. Cell experiments demonstrated that BaP significantly promoted cellular senescence and activated Ras and COX-2. Kaempferol treatment effectively reversed these changes. Conclusion: This study reveals that BaP promotes IPF by inducing epithelial cell senescence via the Ras/COX-2 signaling pathway. Kaempferol may exert anti-fibrotic effects by counteracting this pathway-mediated senescence. These findings provide a theoretical basis for the pulmonary fibrosis effects of BaP and support kaempferol as a potential anti-fibrotic agent.

  • Open Access

    Case Report: IgG4-related lung disease

    by Yehui Li, Yuanbin Luo, Liwen Zhou, Xianmei Zhou

    Immunoglobulin G4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory condition, distinct from classical autoimmune disorders, that can affect multiple organs. Pulmonary involvement often presents with non-specific clinical and radiographic features, contributing to high rates of misdiagnosis and underdiagnosis. Here, we report a rare case of IgG4-related lung disease (IgG4-RLD) to enhance clinical awareness. A 71-year-old female presented with cough. Chest computed tomography (CT) revealed an irregular soft tissue mass in the right middle lobe. All autoantibodies tested were negative, and the serum IgG4 level was within the normal range. The patient showed no response to anti-infective and antitussive therapy, with follow-up CT confirming lesion enlargement. A CT-guided percutaneous lung biopsy was subsequently performed. Histopathology demonstrated infiltration of numerous lymphocytes and plasma cells, along with scattered neutrophils. Immunohistochemistry showed a ratio of IgG4-positive to IgG-positive plasma cells of approximately 42%, and demonstrated approximately 30 IgG4-positive plasma cells per high-power field (HPF). The diagnosis of IgG4-RLD was established based on the 2019 ACR/EULAR International Classification Criteria for IgG4-RD. The patient was subsequently treated with oral prednisone, which led to complete resolution of the cough and near-complete regression of the pulmonary lesion.

  • Exploration of Mechanisms of Keliu Pill on the Inhibition of Lymphangiogenesis in Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation

    by Shuang Yang, Xiao Wu, Tingyu Pan, Weizhou Zhang, Wenpan Peng, Zhichao Wang, Fanchao Feng, Yong Xu, Ying Yang, Hailang He, et al.

    Keliu Pill (KLW) is a Chinese medicine formula that has been shown to be effective in treating non-small cell lung cancer (NSCLC) patients. However, the potential molecular mechanism remains unclear. To explore the underlying mechanism of Keliu Pill (KLW) in treating NSCLC, the network pharmacology was applied to explore the potential mechanism of KLW in the treatment of lung cancer. With oral bioavailability (OB) ≥ 30% and drug-like index (DL) ≥ 0.18 as the filter criteria, the compounds of 6 traditional Chinese medicines (TCMs) from KLW were retrieved on Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform (TCMSP) and supplemented by Traditional Chinese Medicine Comprehensive Database (TCMID). The potential targets corresponding to the active components of the TCMs mentioned above were obtained from TCMSP. Subsequently, the potential underlying action mechanisms of KLW on NSCLC predicted by the network pharmacology analyses were experimentally validated in Lewis lung cancer cell inoculation mice models and co-culture models with Lewis lung cancer cell and tumor-associated macrophages (TAMs). After database search and screening, a total of 20 active ingredients of Astragalus Membranaceus, 21 of Sophare Tonkinensis Radix et Rhizoma, 1 of Mylabris, 3 of Eupolyphaga, 1 of Leech, and 3 of Gecko were obtained. After deleting duplicates, 49 active ingredients were obtained. Thirty important active ingredients in KLW were sorted out by referring to relevant literature. The KEGG pathway enrichment analysis based on the DAVID platform showed that the VEGF-C signaling pathway may be the core signaling pathway associated with KLW in the treatment of NSCLC. The network pharmacological analysis demonstrated that the various components of KLW acted on NSCLC through 29 potential targets such as VEGF-C, VEGF-D, MAPK8, MAPK1, and AKT1. The experiments in vivo indicated KLW could inhibit the transcription and translation of VEGF-C and VEGF-D in tumor tissues. KLW could reduce the proportion of activated TAMs in the tissue. KLW-contained serum may decrease the expression level of VEGF-C and VEGF-D and inhibit the lymphatic lumen formation of human lymphatic endothelial cells. VEGFC and VEGFD were confirmed as the potential KLW-associated targets for NSCLC. KLW may inhibit lymphatic angiogenesis of lung cancer by regulating the function of TAMs.

  • Liquid chromatography-mass spectrometry-based metabolomics study of the protective mechanism of Shenji Guben decoction on chronic obstructive pulmonary disease.

    by Pan Tingyu, Yao Jing, G E Yue, Yang Shuang, Sun Zikai, Wei Yu, W U Jieyu, X U Yong, Zhou Xianmei, H E Hailang

    To investigate the mechanisms of the effect of Shenji Guben (SJGB) decoction on chronic obstructive pulmonary disease (COPD). A murine model of COPD was established through lipopolysaccharide (LPS) nasal drops and passive smoke exposure, followed by evaluation of SJGB decoction efficacy via lung function tests and histological analysis. Non-targeted liquid chromatography-mass spectrometry (LC-MS)-based metabolomics was used to explore the mechanisms of SJGB decoction in COPD. We found that the SJGB decoction effectively reduced inflammatory cell infiltration in the airways and lungs, and improved lung function in the COPD model mice. LC-MS-based metabolomics identified 86 biomarkers in COPD models. Compared to the model group, SJGB decoction significantly altered 34 metabolites. Prostaglandin E2 and DL-Citrulline were highlighted as two representative differential metabolites. MetaboAnalyst 5.0 highlighted glycerophospholipid and riboflavin metabolisms as key pathways affected by SJGB decoction. This study evaluated the protective effect of SJGB decoction against COPD and provided insights into its potential mechanisms in COPD treatment.

  • Open Access

    Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review

    by Xirui Qiu, Yu Wei, Xiaoxiao Wang, Siyan Xu, Yaru Zhang, Hailang He, Xianmei Zhou

    In total, >90 unique anaplastic lymphoma kinase (ALK) rearrangement fusion partners have been identified, each with a unique sensitivity to ALK tyrosine kinase inhibitors, rendering targeted therapy challenging. In the present study, the efficacy of alectinib in a patient with advanced lung adenocarcinoma harbouring a novel ALK-microtubule-associated tumour suppressor candidate 2 (MTUS2) fusion and a rare Striatin 3 (STRN3)-ALK fusion was assessed. A 20-year-old non-smoker was hospitalised with a persistent cough. Subsequent positron emission tomography/computed tomography revealed a tumour in the right lower lobe, with mediastinal, hilar, lymph node and bone metastases. Cranial magnetic resonance imaging also revealed a cerebral metastasis. Bronchoscopic biopsy revealed an adenocarcinoma in the right lower lobe nodule, resulting in a clinical stage IVB diagnosis (cT2bN3bM1c). Targeted next-generation sequencing of tissue and blood samples revealed ALK-MTUS2 and STRN3-ALK fusions. The patient was treated with alectinib as the first-line therapy and a durable partial response was achieved after 3 months, with disappearance of the brain metastases. To the best of our knowledge, the present study represents the first discovery of simultaneous ALK-MTUS2 and STRN3-ALK fusions. The clinical outcome offers potential therapeutic options for patients with rare ALK rearrangements and underscores the necessity for further research on the functions of these fusions.


  • Maiwei Yangfei decoction protects against pulmonary fibrosis by suppressing NLRP3 inflammasome-mediated pyroptosis of alveolar macrophage

    by Dongwei Zhu, Qi Zhao, Tingyu Pan, Le Bai, Yisheng Zhao, Jing Wang, Zhichao Wang, Yong Xu, Xianmei Zhou


  • Nobiletin's role in idiopathic pulmonary fibrosis via the PI3K/AKT/MDM2/p53 signaling pathway

    by Tingyuan Li, Jing Wang, Le Bai, Qi Zhao, Dongwei Zhu, Yong Xu, Yongsheng Wang, Zhichao Wang, Fanchao Feng, Xianmei Zhou

    To explore the therapeutic effects of Nobiletin (NOB) on Idiopathic pulmonary fibrosis (IPF) and to identify its targets and molecular pathways. We verified the inhibitory effect of NOB on the senescence of A549 cells through in vitro experiments, and the inhibitory effect of NOB on the migration ability of fibroblasts was verified by the Transwell experiment. The inhibitory effects of NOB on Idiopathic IPF were subsequently assessed in a mouse model induced by bleomycin (BLM). Through PPI network, gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, the PI3K/AKT/MDM2/p53 signaling pathway was identified as the critical pathway. The key proteins in the signaling pathway were verified by molecular docking and western blotting. NOB showed a great inhibitory effect on A549 cell senescence and Fibroblast migration. Meanwhile, NOB reduced BLM-induced collagen deposition in mouse lung tissues and inhibited alveolar epithelial cell (AEC) senescence. Through PPI network, P53 was screened as a core target of NOB. According to functional enrichment analysis results, the PI3K/AKT signaling was believed to have played an important role. Therefore, we speculate that the PI3K/AKT/MDM2/p53 signaling pathway mediated NOB’s impact on IPF. These findings were validated through molecular docking and western blotting. This study demonstrated that NOB suppressed cell senescence to protect IPF through mediating the PI3K/AKT/MDM2/p53 signaling pathway.


  • Open Access

    Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody

    by Jia-Xin Li, Shi-Yu Tan, Li-Qi Li, Yu-Hong Zheng, Lin Zhao, Hui-Rong Zhu, Hai-Lang He, Yan-Yu Zhang, Run-Ze Li, Tian-Yu Bao, et al.

    Background: KRAS is a commonly mutated gene that is present in approximately 30% of NSCLC patients. Currently, the identification of effective therapies for KRAS-mutant NSCLC is difficult for reasons of the structural and biochemical characteristics of the KRAS protein. Our previous study has revealed that tricin was a bioactive component having selective effects on KRASG12C-mutant NSCLC cell lines. Thus, our aim in this project was to explore the mechanism by which tricin inhibited the progression of KRAS-mutant NSCLC much more deeply.Methods: First of all, we detected the acute toxicity of an intraperitoneal injection of tricin in mice according to the improved up-and-down procedure. Next, we integrated network pharmacology, molecular docking with transcriptomics analysis and biological methods to probe the underlying mechanisms of tricin in the treatment of patients with KRAS-mutant NSCLC. Furthermore, we explored the pharmaceutical effects of combination therapy with tricin and an anti-PD-1 inhibitor. Finally, we detected and analyzed the data from clinical samples to prepare for the clinical translation of tricin.Results: Intraperitoneal injection of tricin resulted in low acute toxicity. In vitro, tricin inhibited the migration, proliferation and colony formation of KRASG12C-mutant NSCLC cells in a dose-dependent manner. Mechanistically, tricin inhibited KRASG12C-mutant NSCLC cell growth primarily by suppressing the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway. SRC was identified as a potentially crucial target. In vivo, combined treatment with tricin and an anti-PD-1 antibody markedly suppressed the growth of tumors. The combination treatment had nearly no toxicity to the organs of the mice. In terms of immune regulation, tricin increased the numbers of CD8+ T lymphocytes and the levels of the functional cytokines TNFα, IFNγ, and Granzyme B. Tricin also increased the numbers of B lymphocytes and disrupted the PD-1/PD-L1 pathway. These results indicated that tricin could compensate for the deficiency of immunotherapy and enhance the antitumor activity of immunotherapy. Moreover, the detection of clinical samples indicated that the rate of SRC positivity was higher in elderly patients with KRAS mutations at the early stage. A positive correlation between the expression of SRC and PD-L1 was observed in tumor tissues.Conclusion: We believe that tricin is a safe and promising agent for the treatment of patients with KRAS-mutated NSCLC. Our study provides an experimental basis for improving the clinical application of traditional Chinese medicine.


  • Mai-wei-yang-fei decoction protects against pulmonary fibrosis by reducing telomere shortening and inhibiting AECII senescence via FBW7/TPP1 regulation

    by Jing Wang, Yang Zhao, Yun Wei, Tingyuan Li, Tongxing Huang, Tingyu Pan, Jieyu Wu, Le Bai, Dongwei Zhu, Qi Zhao, et al.


  • Identification of potential mechanisms of Schisandrin B in the treatment of idiopathic pulmonary fibrosis by integrating network pharmacology and experimental validation

    by Tingyu Pan, Jieyu Wu, Xirui Qiu, Dongwei Zhu, Jing Wang, Tingyuan Li, Zhichao Wang, Fanchao Feng, Yong Xu, Xianmei Zhou

    Idiopathic pulmonary fibrosis (IPF) is a worsening fibrotic condition characterized by a short survival rate and limited treatment options. This study evaluates the potential anti-fibrotic properties of Schisandrin B (Sch B) through network pharmacology and experimental validation. A mouse model of bleomycin-induced pulmonary fibrosis was established, and the modeled mice were treated with Sch B at three doses (20 mg/kg/day, 40 mg/kg/day, and 80 mg/kg/day). A fibrotic model was developed in NIH/3T3 cells by treating them with TGF-β (10 ng/mL) and administering Sch B at various concentrations (10, 20, and 40 µM). The results revealed that Sch B treatment delayed the development of bleomycin-induced pulmonary fibrosis and substantially decreased the transcription levels of collagen I and α-SMA in TGF-β-induced fibroblasts. Core targets were screened with protein-protein interaction network analysis, molecular complex detection (MCODE), and CytoHubba plugin. The application of Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and molecular docking highlighted the significance of the HIF-1α signaling pathway in the potential mechanism of Sch B in IPF therapy. Western blot, PCR, and immunofluorescence were performed to validate the effects of Sch B on HIF-1α. In vivo and in vitro, Sch B administration reduced HIF-1α expression. These outcomes provide valuable insights into the potential mechanism by which Sch B delays IPF development, with HIF-1α potentially serving as a key target. However, further investigation is warranted to assess the safety and efficacy of Sch B in clinical settings.